UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2020

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 033-33263

 

Jacksam Corporation

(Exact name of registrant as specified in its charter)

 

Nevada

 

46-3566284

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

30191 Avenida De Las Banderas Suite B

Rancho Santa Margarita, CA

 

92688

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (800) 605-3580

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No o

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ☒

 

As of November 5, 2020, the registrant had 65,790,040 shares of common stock, $0.001 par value per share, outstanding.

 

 

 

 

TABLE OF CONTENTS

 

 

Page

 

PART I — FINANCIAL INFORMATION

 

Item 1.

Financial Statements

 

 

Unaudited Condensed Consolidated Balance Sheets at September 30, 2020 and Audited Condensed Consolidated Balance Sheets at December 31, 2019

 

4

 

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2019

 

5

 

 

Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and Nine Months Ended September 30, 2020 and 2019

 

6

 

 

Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019

 

7

 

Notes to Unaudited Condensed Consolidated Financial Statements

 

8

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

24

 

Item 4.

Controls and Procedures

24

 

PART II — OTHER INFORMATION

 

Item 1.

Legal Proceedings

25

 

Item 1A.

Risk Factors

25

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

25

 

Item 3.

Defaults Upon Senior Securities

25

 

Item 4.

Mine Safety Disclosures

25

 

Item 5.

Other Information

25

 

Item 6.

Exhibits

26

 

Signatures

27

 

 
2

 

 

Forward-Looking Statements

 

For purposes of this report, unless otherwise indicated or the context otherwise requires, all references herein to “Jacksam Corporation,” “the Company,” “we,” “us,” and “our,” refer to Jacksam Corporation, a Nevada corporation.

 

This Quarterly Report on Form 10-Q, or this Report, contains forward-looking statements. Any and all statements contained in this Report that are not statements of historical fact may be deemed forward-looking statements. Terms such as “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro-forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future” and terms of similar import (including the negative of any of the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain one or more of these identifying terms. Forward-looking statements in this Report may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of our cartridge filling machines, cartridge capping machines and cartridges, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above.

 

The forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon our current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which we have no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

 

 
3

Table of Contents

 

Jacksam Corporation

Consolidated Balance Sheets

 

 

 

 

(Unaudited) 

 

 

(Audited) 

 

 

 

September 30,

 

 

December 31,

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$ 598,964

 

 

$ 453,623

 

Accounts receivable, net

 

 

309,830

 

 

 

105,510

 

Inventory, net

 

 

151,726

 

 

 

189,841

 

Prepaid expenses

 

 

124,507

 

 

 

251,539

 

Total Current Assets

 

 

1,185,027

 

 

 

1,000,513

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

3,852

 

 

 

13,280

 

Right of use asset - operating lease

 

 

-

 

 

 

9,299

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$ 1,188,879

 

 

$ 1,023,092

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$ 671,025

 

 

$ 696,633

 

Deferred revenue

 

 

986,905

 

 

 

1,343,983

 

Convertible notes payable, current portion

 

 

783,666

 

 

 

1,067,983

 

Notes payable, current portion

 

 

366,946

 

 

 

145,331

 

Right of use liability - operating lease

 

 

-

 

 

 

9,837

 

Derivative liability

 

 

3,612,585

 

 

 

504,750

 

Accrued liabilities - other

 

 

1,642,118

 

 

 

1,642,118

 

Total Current Liabilities

 

 

8,063,245

 

 

 

5,410,635

 

 

 

 

 

 

 

 

 

 

Notes payable, net of current portion

 

 

304,616

 

 

 

-

 

Other long-term liabilities

 

 

-

 

 

 

220,000

 

Total Liabilities

 

 

8,367,861

 

 

 

5,630,635

 

 

 

 

 

 

 

 

 

 

Commitment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit:

 

 

 

 

 

 

 

 

Preferred stock - 10,000,000 authorized, $0.001 par value, 0 shares issued and outstanding

 

 

-

 

 

 

-

 

Common stock - 90,000,000 authorized, $0.001 par value, 64,246,830 and 62,871,972 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

 

 

64,247

 

 

 

62,872

 

Additional paid-in capital

 

 

4,240,896

 

 

 

3,396,369

 

Shares payable, consisting of 11,089,433 and 0 shares of common shares as of September 30, 2020 and December 31, 2019, respectively

 

 

1,978,525

 

 

 

-

 

Accumulated deficit

 

 

(13,462,650 )

 

 

(8,066,784 )

Total Stockholders' Deficit

 

 

(7,178,982 )

 

 

(4,607,543 )

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders' Deficit

 

$ 1,188,879

 

 

$ 1,023,092

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements 

 

 
4

Table of Contents

 

Jacksam Corporation

Consolidated Statements of Operations

For the Three and Nine Months Ended September 30, 2020 and 2019

(Unaudited)

 

 

 

Three Months

Ended

 

 

Three Months

Ended

 

 

Nine Months

Ended

 

 

Nine Months

Ended

 

 

 

September 30,

2020

 

 

September 30,

2019

 

 

September 30,

2020

 

 

September 30,

2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

 

$ 735,604

 

 

$ 1,303,053

 

 

$ 2,022,307

 

 

$ 4,253,728

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of Sales

 

 

331,863

 

 

 

818,442

 

 

 

879,637

 

 

 

3,341,083

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

403,741

 

 

 

484,611

 

 

 

1,142,670

 

 

 

912,645

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries and wages (including contractors)

 

 

306,307

 

 

 

465,339

 

 

 

786,004

 

 

 

2,169,334

 

Other selling, general and administrative expenses

 

 

194,316

 

 

 

468,208

 

 

 

561,154

 

 

 

1,750,657

 

Total Operating Expenses

 

 

500,623

 

 

 

933,547

 

 

 

1,347,158

 

 

 

3,919,991

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(96,882 )

 

 

(448,936 )

 

 

(204,488 )

 

 

(3,007,346 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other expense (income)

 

 

-

 

 

 

(25 )

 

 

(6,154 )

 

 

14,341

 

Derivative loss

 

 

2,000,866

 

 

 

5,047,111

 

 

 

3,512,675

 

 

 

5,181,924

 

Interest expense

 

 

62,945

 

 

 

448,430

 

 

 

1,684,857

 

 

 

516,207

 

Total Other Expenses

 

 

2,068,811

 

 

 

5,495,516

 

 

 

5,191,378

 

 

 

5,712,472

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$ (2,165,693 )

 

$ (5,944,452 )

 

$ (5,395,866 )

 

$ (8,719,818 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

$ (0.03 )

 

$ (0.10 )

 

$ (0.09 )

 

$ (0.15 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and Diluted

 

 

62,803,497

 

 

 

61,591,972

 

 

 

62,531,289

 

 

 

58,629,486

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements 

 

 
5

Table of Contents

 

Jacksam Corporation

Consolidated Statements of Stockholders' Deficit

For the Three and Nine Months Ended September 30, 2020 and 2019

(Unaudited)

 

 

 

Common Stock, $.001 Par Value

 

 

Paid-In

 

 

Shares

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Payable

 

 

Deficit

 

 

Deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2018

 

 

48,272,311

 

 

$ 48,272

 

 

$ 10,661

 

 

$ -

 

 

$ (4,519,497 )

 

$ (4,460,564 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cumulative effect of ASU 2016-02

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,407 )

 

 

(2,407 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued for debt conversion

 

 

10,579,661

 

 

 

10,580

 

 

 

3,192,920

 

 

 

-

 

 

 

-

 

 

 

3,203,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of common stock warrants

 

 

2,000,000

 

 

 

2,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible debt imputed interest

 

 

-

 

 

 

-

 

 

 

22,945

 

 

 

-

 

 

 

-

 

 

 

22,945

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(669,243 )

 

 

(669,243 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2019

 

 

60,851,972

 

 

$ 60,852

 

 

$ 3,226,526

 

 

$ -

 

 

$ (5,191,147 )

 

$ (1,903,769 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of common stock warrants

 

 

900,000

 

 

 

900

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

900

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible debt imputed interest

 

 

-

 

 

 

-

 

 

 

150

 

 

 

-

 

 

 

-

 

 

 

150

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,106,123 )

 

 

(2,106,123 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2019

 

 

61,751,972

 

 

$ 61,752

 

 

$ 3,226,676

 

 

$ -

 

 

$ (7,297,270 )

 

$ (4,008,842 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible debt imputed interest

 

 

-

 

 

 

-

 

 

 

151

 

 

 

-

 

 

 

-

 

 

 

151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,944,452 )

 

 

(5,944,452 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, September 30, 2019

 

 

61,751,972

 

 

$ 61,752

 

 

$ 3,226,827

 

 

$ -

 

 

$ (13,241,722 )

 

$ (9,953,143 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2019

 

 

62,871,972

 

 

$ 62,872

 

 

$ 3,396,369

 

 

$ -

 

 

$ (8,066,784 )

 

$ (4,607,543 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible debt imputed interest

 

 

-

 

 

 

-

 

 

 

151

 

 

 

-

 

 

 

-

 

 

 

151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock issued for debt conversion

 

 

476,191

 

 

 

476

 

 

 

166,191

 

 

 

1,333,333

 

 

 

-

 

 

 

1,500,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sale of common stock units

 

 

-

 

 

 

-

 

 

 

-

 

 

 

356,470

 

 

 

-

 

 

 

356,470

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Extinguishment of derivative liability due to conversion

 

 

-

 

 

 

-

 

 

 

606,048

 

 

 

-

 

 

 

-

 

 

 

606,048

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,262,535 )

 

 

(5,262,535 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2020

 

 

63,348,163

 

 

$ 63,348

 

 

$ 4,168,759

 

 

$ 1,689,803

 

 

$ (13,329,319 )

 

$ (7,407,409 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible debt imputed interest

 

 

-

 

 

 

-

 

 

 

151

 

 

 

-

 

 

 

-

 

 

 

151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sale of common stock units

 

 

-

 

 

 

-

 

 

 

-

 

 

 

168,080

 

 

 

-

 

 

 

168,080

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares issued for deferred finance costs

 

 

388,667

 

 

 

389

 

 

 

72,345

 

 

 

-

 

 

 

-

 

 

 

72,734

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares issued under share-lending arrangement

 

 

1,443,333

 

 

 

1,443

 

 

 

(1,443 )

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares returned under share-lending arrangement

 

 

(933,333 )

 

 

(933 )

 

 

933

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,032,362

 

 

 

2,032,362

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, June 30, 2020

 

 

64,246,830

 

 

$ 64,247

 

 

$ 4,240,745

 

 

$ 1,857,883

 

 

$ (11,296,957 )

 

$ (5,134,082 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible debt imputed interest

 

 

-

 

 

 

-

 

 

 

151

 

 

 

-

 

 

 

-

 

 

 

151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of common stock units

 

 

-

 

 

 

-

 

 

 

-

 

 

 

120,642

 

 

 

-

 

 

 

120,642

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,165,693 )

 

 

(2,165,693 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, September 30, 2020

 

 

64,246,830

 

 

$ 62,247

 

 

$ 4,240,896

 

 

$ 1,978,525

 

 

$ (13,462,650 )

 

$ (7,178,982 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 

 
6

Table of Contents

 

Jacksam Corporation

Consolidated Statements of Cash Flows

For the Nine Months Ended September 30, 2020 and 2019

(Unaudited)

 

 

 

2020

 

 

2019

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net loss

 

$ (5,395,866 )

 

$ (8,719,818 )

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation expense

 

 

9,428

 

 

 

799

 

Imputed interest

 

 

453

 

 

 

23,246

 

Amortization of debt discount

 

 

1,594,924

 

 

 

486,458

 

Derivative loss

 

 

3,512,675

 

 

 

5,181,924

 

Inventory impairment

 

 

-

 

 

 

39,045

 

Net change in:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(204,320 )

 

 

(298,955 )

Inventory

 

 

38,115

 

 

 

553,568

 

Prepaid expenses

 

 

127,032

 

 

 

(49,775 )

Right of use asset

 

 

9,299

 

 

 

-

 

Other assets

 

 

-

 

 

 

-

 

Accounts payable and accrued expenses

 

 

(23,958 )

 

 

250,127

 

Right of use liability

 

 

(9,837 )

 

 

-

 

Other long-term liabilities

 

 

(220,000 )

 

 

268,125

 

Deferred revenue

 

 

(357,078 )

 

 

463,167

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

 

(919,133 )

 

 

(1,802,089 )

 

 

 

 

 

 

 

 

 

Cash Flows from Investing Activities

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

Proceeds from convertible notes payable

 

 

388,900

 

 

 

1,791,666

 

Payments of debt issuance cost

 

 

(43,300 )

 

 

(132,848 )

Payments on convertible notes payable

 

 

(630,000 )

 

 

(130,000 )

Proceeds from notes payable

 

 

591,900

 

 

 

-

 

Payments on notes payable

 

 

(89,426 )

 

 

(70,912 )

Proceeds from sale of common stock units

 

 

846,400

 

 

 

-

 

Proceeds from exercise of common stock warrants

 

 

-

 

 

 

2,900

 

 

 

 

 

 

 

 

 

 

Net cash provided by financing activities

 

 

1,064,474

 

 

 

1,460,806

 

 

 

 

 

 

 

 

 

 

Net Change in Cash

 

 

145,341

 

 

 

(341,283 )

 

 

 

 

 

 

 

 

 

Cash Balance, Beginning of Period

 

 

453,623

 

 

 

1,074,105

 

 

 

 

 

 

 

 

 

 

Cash Balance, End of Period

 

$ 598,964

 

 

$ 732,822

 

 

 

 

 

 

 

 

 

 

Cash paid for:

 

 

 

 

 

 

 

 

Income taxes

 

$ -

 

 

$ -

 

Interest

 

$ 70,073

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Non-cash transactions:

 

 

 

 

 

 

 

 

Common stock issued to settle convertible notes payable

 

$ 1,500,000

 

 

$ 3,203,500

 

Derivative liability recognized at issuance of warrants

 

$ 201,208

 

 

$ 1,658,818

 

Extinguishment of derivative to conversion and repayment

 

$ 390,383

 

 

$ -

 

Common stock issued for deferred finance costs

 

$ 72,734

 

 

$ -

 

Capitalization of right of use asset for operating lease

 

$ -

 

 

$ 44,138

 

     

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements 

 

 
7

Table of Contents

 

Jacksam Corporation

Notes to Unaudited Condensed Consolidated Financial Statements

 

Note 1: Organization and Nature of Operations

 

Jacksam Corporation dba Convectium is a technology company focused on developing and commercializing products utilizing an open-source technology platform. The Company services the medical and recreational cannabis, hemp and CBD segments of the larger e-cigarette and vaporizer markets.

 

Prior to July 2019, the Company’s product line primarily consisted of the 710 Shark cartridge filling machine, the 710 Captain cartridge capping machine, and proprietary cartridges. Since July 2019, the Company has added the eShark cartridge filling machine and PreRoll-Er cannabis pre-roll filling machine into its product line and discontinued the sales of proprietary cartridges.

 

During the fourth quarter of 2019, the Company entered into a strategic partnership with Jupiter Research, LLC. The partnership highlights the leverage of existing customer base and sales force of both companies to distribute the Company’s automation machines and pre-rack solution, and Jupiter Research’s C-Cell cartridges under a profit-sharing agreement.

 

During the second quarter of 2020, the Company entered into a strategic partnership with 14th Round Inc. The partnership highlights the sales force collaboration, equipment R&D collaboration, and marketing collaborations.

 

During the third quarter of 2020, the Company introduced the PreRoll-Er automatic cannabis pre-roll filling machine to the U.S. market.

 

The Company’s customers are primarily businesses operating in jurisdictions that have some form of cannabis legalization. These businesses include medical and recreational dispensaries, large and small-scale processors and growers, multi-state operators, and distributors. The Company utilizes its direct sales force, website, strategic partners’ sales force, independent sales representatives, and a wide range of referral network to sell its products.

 

The Company was originally organized under the laws of the State of Nevada on September 21, 1989 under the name of Fulton Ventures, Inc. Effective November 16, 2009, management at that time changed the name of Fulton Ventures, Inc. to China Grand Resorts, Inc. After the September 30, 2014 10-Q filing, the management of China Grand Resorts, Inc. abandoned the Company and its subsidiaries were taken back by Chinese national companies in China who owned them. The remaining parent company, China Grand Resorts, Inc., became a dormant company until 2016 when a new shareholder Bryan Glass became the majority shareholder and owner of the Company.

 

On September 14, 2018, the Company’s wholly owned subsidiary, Jacksam Acquisition Corp., a corporation formed in the State of Nevada on September 11, 2018, or the Acquisition Sub, merged with and into Jacksam, a corporation incorporated in the State of Delaware in August 2013.

 

On November 5, 2018, current management merged Jacksam into the parent Company, China Grand Resorts, Inc. In connection with the transaction, current management amended articles of incorporation to change the Company’s name from China Grand Resorts, Inc. to Jacksam Corporation dba Convectium.

 

Since the Merger, the Company has been operated under the control of current management and continued to operate the business of Jacksam Corporation, described herein, as the Company’s sole business.

 

In accordance with the terms of the Exchange Agreement, and in connection with the completion of the acquisition, on the Closing Date, the Company issued 45,000,000 shares of common stock at par value $0.001 per share to the Jacksam shareholders in exchange for all of the issued and outstanding shares of Jacksam. In addition, the previous owners of China Grand Resorts, Inc. returned 30,000,000 shares of common stock to the treasury of the Company. Following the acquisition, there was a total of 48,272,311 shares of common stock issued and outstanding, of which 3,272,311 were held by shareholders of the Company prior to the merger. In connection with the above transaction, $340,000 was paid to the former controlling shareholder related to the return of 30,000,000 shares of common stock.

 

In accordance with “reverse merger” or “reverse acquisition” accounting treatment, the historical financial statements of China Grand Resorts, Inc., as of period ends and for periods ended prior to the Merger, will be replaced with the historical financial statements of Jacksam, prior to the Merger, in all future filings with the SEC.

 

 
8

Table of Contents

 

Note 2: Significant Accounting Policies

 

Basis of Preparation

 

The interim unaudited consolidated financial statements as of September 30, 2020, and for the three and nine months ended September 30, 2020 and 2019, have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. They do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes filed with the SEC for the year ended December 31, 2019.

 

Inventory

 

Inventories are stated at the lower of cost, determined on the first-in, first-out (FIFO) method or net realizable value. Cost principally consists of the purchase price (adjusted for lower of cost or market), customs, duties, and freight. The Company periodically reviews historical sales activity to determine potentially obsolete items and evaluates the impact of any anticipated changes in future demand.

 

The September 30, 2020 and December 31, 2019 inventory consisted entirely of finished goods. The Company will maintain an allowance based on specific inventory items that have shown no activity over a 24-month period. The Company tracks inventory as it is disposed, scrapped or sold at below cost to determine whether additional items on hand should be reduced in value through an allowance method. As of September 30, 2020 and December 31, 2019, the Company has determined that no allowance is required.

 

Revenue Recognition

 

The Company derives revenues from the sale of machines and consumable products. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring those goods or services.

 

Revenue is recognized based on the following five step model:

 

 

-

Identification of the contract with a customer

 

-

Identification of the performance obligations in the contract

 

-

Determination of the transaction price

 

-

Allocation of the transaction price to the performance obligations in the contract

 

-

Recognition of revenue when, or as, the Company satisfies a performance obligation

 

Performance Obligations

 

Sales of machines and consumable products are recognized when all the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectability is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. The customer has a 10-day period to inspect the equipment and may return the product if it does not meet the agreed-upon specifications. For contracts with multiple performance obligations, the Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The Company uses an observable price to determine the stand-alone selling price for separate performance obligations or a cost-plus margin approach when one is not available. Historically, the Company’s contracts have not had multiple performance obligations. Most the Company’s performance obligations are recognized at a point in time related to the sale of machines and consumable products.

 

 
9

Table of Contents

 

Sales, value add, and other taxes collected concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. Payment terms between invoicing and when payment is due is less than one year. As of September 30, 2020, none of the Company’s contracts contained a significant financing component.

 

The Company elected the practical expedient to not adjust the amount of revenue to be recognized under a contract with an end user for the effects of time value of money when the timing difference between receipt of payment and recognition of revenue is less than one year. 

 

The majority of the Company’s contracts offer an assurance-type warranty of the products at no additional cost for a period of 3 years. Assurance-type warranties provide a customer with assurance that the related product will function as the parties intended because it complies with agreed-upon specifications. Such warranties do not represent a separate performance obligation. At the time a sale is recognized, the Company estimated future warranty costs, which were trivial.

 

Transaction Price Allocated to the Remaining Performance Obligations

 

At a given point in time, the Company may have collected payment for future sales of product to begin production. These transactions are deferred until the product transfers to the customer and the performance obligation is considered complete. As of September 30, 2020, $986,905 in revenue is expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. The Company expects to recognize all of the Company’s unsatisfied (or partially unsatisfied) performance obligations as revenue in the next twelve months.

 

Contract Costs

 

Costs incurred to obtain a customer contract are not material to the Company. The Company elected to apply the practical expedient to not capitalize contract costs to obtain contracts with a duration of one year or less, which are expensed and included within cost of goods and services.

 

Critical Accounting Estimates

 

Estimates are used to determine the amount of variable consideration in contracts, the standalone selling price among separate performance obligations and the measure of progress for contracts where revenue is recognized over time. The Company reviews and updates these estimates regularly.

 

Disaggregation of Revenue

 

All machine sales and most consumable products sales are completed in North America.

 

 

 

Three Months

Ended

September 30,

2020

 

 

Three Months

Ended

September 30,

2019

 

 

Nine Months

Ended

September 30,

2020

 

 

Nine Months

Ended

September 30,

2019

 

Machine sales

 

$ 685,635

 

 

$ 945,199

 

 

$ 1,802,305

 

 

$ 2,166,652

 

Consumable product sales

 

 

49,969

 

 

 

357,854

 

 

 

200,002

 

 

 

2,087,076

 

Total sales

 

$ 735,604

 

 

$ 1,303,053

 

 

$ 2,022,307

 

 

$ 4,253,728

 

 

Net Loss Per Common Share

 

Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, the Company excludes stock options and other stock-based awards, including shares issued as a result of option exercises that are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. During the nine months ended September 30, 2020 and 2019, common stock equivalents were excluded from the calculation of diluted net loss per common share, as their effect was anti-dilutive due to the net loss incurred. Therefore, basic and diluted net loss per share was the same in all periods presented.

 

 
10

Table of Contents

 

The Company had 13,971,879 and 12,611,109 potentially dilutive securities that have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2020 and 2019, respectively, as they would be anti-dilutive. Additionally, as of September 30, 2020 there were a total of 11,089,433 shares to be issued related to conversions of debt and stock unit sales during the nine months September 30, 2020 that were excluded from the computation of weighted average shares outstanding.

 

Going Concern

 

The Company’s financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has negative working capital, recurring losses, and does not have a source of revenues sufficient to cover its operating costs. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The ability of the Company to continue as a going concern is dependent upon its ability to successfully execute the business plan and attain profitable operations. The accompanying financial statements do not include any adjustments that may be necessary if the Company is unable to continue as a going concern.

 

In the coming year, the Company’s foreseeable cash requirements will relate to continual development of the operations of its business, maintaining its good standing and making the requisite filings with the SEC, and the payment of expenses associated with operations and business developments. The Company may experience a cash shortfall and be required to raise additional capital.

 

Historically, it has mostly relied upon convertible notes payable and cash flows from operations to finance its operations and growth. Management may raise additional capital by retaining net earnings or through future private offerings of the Company’s stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing. The Company’s failure to do so could have a material and adverse effect upon it and its shareholders.

 

Recently Issued Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective and will not have a material effect on its consolidated financial position or results of operations upon adoption.

 

Note 3: Property and Equipment

 

Property and equipment consist of the following:

 

 

 

September 30,

2020

 

 

December 31,

2019

 

Furniture and fixtures

 

$ 10,425

 

 

$ 10,425

 

Equipment

 

 

7,579

 

 

 

7,579

 

Trade show display

 

 

2,640

 

 

 

2,640

 

Total

 

 

20,644

 

 

 

20,644

 

Less: Accumulated depreciation

 

 

(16,792 )

 

 

(7,364 )

Property and equipment net

 

$ 3,852

 

 

$ 13,280

 

 

Depreciation expense amounted to $504 and $9,428 for the three and nine months ended September 30, 2020, respectively, and $267 and $799 for the three and nine months ended September 30, 2019, respectively.

 

 
11

Table of Contents

 

Note 4: Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses consist of the following:

 

 

 

September 30,

2020

 

 

December 31,

2019

 

 

 

 

 

 

 

 

Accounts payable

 

$ 256,384

 

 

$ 347,850

 

Credit cards payable

 

 

16,402

 

 

 

48,743

 

Accrued interest

 

 

24,186

 

 

 

4,778

 

Sales tax payable

 

 

140,303

 

 

 

130,262

 

Accrued officer consulting cost

 

 

233,750

 

 

 

165,000

 

Total Accounts payable and accrued expenses

 

$ 671,025

 

 

$ 696,633

 

 

Note 5: Notes Payable

 

A summary of Notes Payable are as follows:

 

 

 

September 30,

2020

 

 

December 31,

2019

 

Note payable dated December 31, 2019, bearing interest at 3% monthly, maturing February 29, 2020 (amended on April 22, 2020)

 

 

-

 

 

$ 164,835

 

Note payable dated February 6, 2020, bearing interest at 3% monthly, maturing May 27, 2022 (amended on April 22, 2020)

 

 

122,662

 

 

 

-

 

SBA PPP loan dated April 17, 2020, bearing interest at 1%, maturing April 17, 2022

 

 

399,000

 

 

 

-

 

SBA EIDL loan dated May 26, 2020, bearing interest at 3.75%, maturing May 26, 2050

 

 

149,900

 

 

 

-

 

Total notes payable

 

 

671,562

 

 

 

164,835

 

Less: unamortized discount and deferred financing costs

 

 

-

 

 

 

(19,504 )

Less: current portion

 

 

(366,946 )

 

 

(145,331 )

Long-term portion of notes payable

 

$ 304,616

 

 

$ -

 

 

On December 31, 2019, the Company entered into an inventory financing arrangement with a single lender, whereby $150,000 was paid by the lender directly to a vendor to secure inventory for the sales to customers in January 2020. The Company will repay $164,835 of principal and interest by February 29, 2020. The interest and fees of $14,835 were recorded as debt discount and were amortized through the maturity date. The Company also paid a deferred finance cost of $5,000 which was amortized through the maturity date. The Company entered into a second agreement on February 6, 2020 with the same lander for an additional $43,000 of funding. The Company will repay $47,253 at maturity on April 6, 2020. On April 22, 2020, these two notes payable were refinanced with the lender into a single agreement whereby the Company will make an initial repayment of $74,231 and 24 monthly payments of $7,467, for total payments of $253,439. This amendment was accounted for as a modification of the debt.

 

In April 2020, the Company received $399,000 under the Small Business Administration’s Payroll Protection Program. The loan bears interest at a fixed rate of 1%, and matures on April 17, 2022, payable monthly with payments beginning six months after issuance. In accordance with the terms of the Payroll Protection Program, a portion of this loan may be forgiven if the loan proceeds are used for payroll, mortgage, rent and utility costs, but no more than 25% of the forgiveness amount can be related to nonpayroll costs.

 

 
12

Table of Contents

 

On June 2, 2020, the Company received $150,000 under the Small Business Administration’s Economic Injury Disaster Loan. The loan bears interest at a fixed rate of 3.75%, and matures on May 26, 2050, payable monthly with payments of $731 beginning twelve months after issuance. The loan gives the Small Business Administration a security interest in all assets of the Company.

 

The Company amortized $23,757 of debt discount and deferred finance costs to interest expense related to notes payable.

 

Note 6: Convertible Notes Payable

 

The following table summarizes outstanding convertible notes as of September 30, 2020 and December 31, 2019:

 

 

 

September 30,

2020

 

 

December 31,

2019

 

2017 Notes, maturing December 2020, currently past due

 

$ 15,000

 

 

$ 15,000

 

June 2019 Notes, maturing March 25, 2020, currently past due

 

 

448,888

 

 

 

2,018,889

 

December 2019 Notes, maturing June 10, 2020

 

 

-

 

 

 

560,000

 

June 2020 Note 1, maturing June 4, 2021

 

 

175,000

 

 

 

-

 

June 2020 Note 2, maturing June 24, 2021

 

 

129,000

 

 

 

-

 

June 2020 Note 3, maturing June 24, 2021

 

 

129,000

 

 

 

-

 

Total

 

 

896,888

 

 

 

2,593,889

 

Less: Debt discount and deferred finance costs on short-term convertible notes

 

 

(113,222 )

 

 

(1,525,906 )

Less: Current convertible notes payable, net of discount

 

 

(783,666 )

 

 

(1,067,983 )

 

 

 

 

 

 

 

 

 

Total long-term convertible notes payable, net

 

$ -

 

 

$ -

 

 

In June and July 2019, the Company issued convertible notes to 10 investors with a principal amount of $2,388,889, receiving $1,583,333 in net cash proceeds (the “June 2019 Notes”). The June 2019 Notes had an original issue discount of $238,889, and the Company incurred an interest charge deducted from the gross proceeds of $358,333, based on a 15% stated rate. The total of $597,222 was recorded as debt discount. Additionally, the Company paid $132,848 of financing costs, which were recorded as a reduction of the carrying value of the debt. The deferred financing costs and debt discounts are being amortized using the effective interest method through the maturity of the June 2019 Notes. The June 2019 Notes matured on March 25, 2020 and are convertible into the Company’s common stock at a per share price of $0.35 at any time subsequent to the issuance date. The June 2019 Notes contain a down round feature, whereby any sale of common stock or common stock equivalent at a price per share lower than the conversion price of the June 2019 Notes will result in the conversion price being lowered to the new price. The warrants contain the same down round feature as the notes. As a result of a dilutive issuance during the six months ended June 30, 2020, the exercise price of the remaining notes payable and the warrants is currently $0.18 per share. The convertible debt outstanding as of September 30, 2020 was convertible into 2,493,827 shares of common stock.

 

During the nine months ended September 30, 2020, $1,500,000 of the principal on the June 2019 Notes was converted into 7,142,852 shares of common stock, of which 476,191 were issued by September 30, 2020. On May 19, 2020, the holder of $444,444 of the notes agreed to extend the repayment period to December 31, 2020. There were no other changes to terms of the convertible notes payable, and the amendment was accounted for as a debt modification.

 

In December 2019, the Company issued convertible notes to an institutional investor with a principal amount of $560,000 (the “December 2019 Notes”) with an original issue discount of $56,000 and a maturity date of June 10, 2020. The Company paid $44,000 of deferred finance costs. The Company also issued 186,667 shares of common stock to the lender of the December 2019 Notes as deferred finance costs, valued at $81,200 based on the closing price of the stock at the date of borrowing. This lender also received 933,333 shares of common stock valued at $406,000 as a share lending arrangement, which the company recorded as contra-equity. The shares were returned to the Company when the debt was repaid in full in June 2020, by the maturity date.

 

 
13

Table of Contents

 

On June 4, 2020, the Company issued a convertible note to an institutional investor with a principal amount of $175,000 (the “June 2020 Note 1”) bearing interest at 15% with an original issue discount of $17,500 and a maturity date of June 4, 2021. The Company paid $17,100 of deferred finance costs. The Company also issued 116,667 shares of common stock to the lender of the June 2020 Note 1 as deferred finance costs, valued at $23,333 based on the closing price of the stock at the date of borrowing. In May 2020, the Company issued 100,000 shares of common stock to an investment bank that were recorded as a deferred finance costs, valued at $15,000 based on the closing price of the stock at the date of issuances. This lender also received 583,333 shares of common stock valued at $116,667 under a share lending arrangement, which the company recorded as contra-equity. The shares may be returned to the Company if the debt is satisfied in full by the maturity date. If the debt is not repaid by the maturity date or an event of default occurs, the shares are concerned fully earned, and the fair value of the shares will be amortized in full to expense.

 

On June 24, 2020, the Company issued convertible notes to an institutional investor with a principal amount of $129,000 (the “June 2020 Note 2”) bearing interest at 15% with an original issue discount of $12,900 and a maturity date of June 24, 2021. The Company paid $13,500 of deferred finance costs. The Company also issued 86,000 shares of common stock to the lender of the June 2020 Note 2 as deferred finance costs, valued at $17,200 based on the closing price of the stock at the date of borrowing. This lender also received 430,000 shares of common stock valued at $86,000 as a share lending arrangement, which the company recorded as contra-equity. The shares may be returned to the Company if the debt is satisfied in full by the maturity date. If the debt is not repaid by the maturity date or an event of default occurs, the shares are concerned fully earned, and the fair value of the shares will be amortized in full to expense.

 

On June 24, 2020, the Company entered into a convertible note agreement with an institutional investor for a principal amount of $129,000 (the “June 2020 Note 3”) bearing interest at 15% with an original issue discount of $12,900 and a maturity date of June 24, 2021. The proceeds of this loan were received in July 2020. The Company paid $13,500 of deferred finance costs. The Company issued 86,000 shares of common stock to the lender of the June 2020 Note 3 as deferred finance costs, valued at $17,200 based on the closing price of the stock at the date of borrowing. This lender also received 430,000 shares of common stock valued at $86,000 as a share lending arrangement, which the company recorded as contra-equity. The shares may be returned to the Company if the debt is satisfied in full by the maturity date. If the debt is not repaid by the maturity date or an event of default occurs, the shares are concerned fully earned, and the fair value of the shares will be amortized in full to expense.

 

The Company amortized $1,572,817 and $486,458 of debt discount and deferred finance costs to interest expense related to convertible notes payable during the nine months ended September 30, 2020 and 2019, respectively. Accrued interest on notes payable and convertible notes payable was $24,186 and $4,776 as of September 30, 2020 and December 31, 2019, respectively.

 

The Company evaluated the embedded conversion features of the convertible debt instruments and the warrants discussed above and determined that the conversion options and the warrants should be accounted for as derivative liabilities. The fair values of the conversion option and the attached warrants were estimated using a binomial model with the following assumptions:

 

 

 

As of September 30, 2020

 

 

 

Conversion Option

 

 

Warrants

 

Volatility

 

 

126.13 %

 

93.4-101.8

%

Dividend Yield

 

 

0 %

 

 

0 %

Risk-free rate

 

 

0.11 %

 

 

0.16 %

Expected term

 

0.50 years

 

 

3-4 years

 

Stock price

 

$ 0.42

 

 

$ 0.42

 

Exercise price

 

$ 0.18

 

 

$

0.18-0.30

 

Derivative liability fair value

 

$ 662,212

 

 

$ 2,950,373

 

 

 
14

Table of Contents

 

All fair value measurements related to the derivative liabilities are considered significant unobservable inputs (Level 3) under the fair value hierarchy of ASC 820. The table below presents the change in the fair value of the derivative liability during the nine months ended September 30, 2020:

 

Fair value as of December 31, 2019

 

$ 504,750

 

Fair value on the date of issuance related to warrants issued

 

 

201,208

 

Extinguishment due to repayment of debt

 

 

(356,007 )

Extinguishment due to conversion of debt

 

 

(606,048 )

Loss on change in fair value of derivatives

 

 

3,868,682

 

Fair value as of September 30, 2020

 

$ 3,612,585

 

 

Note 7: Equity

 

Common Stock

 

As of September 30, 2020, the authorized capital stock of the Company consists of 100,000,000 shares, of which 90,000,000 shares are designated as common stock and 10,000,000 shares of preferred stock.

 

During the nine months ended September 30, 2020, the Company issued 476,191 shares of common stock related to the conversion of $166,667 of Convertible Notes Payable. Additionally, principal of $1,333,333 was converted into 6,666,661 shares of common stock that have not yet been issued.

 

During the nine months ended September 30, 2020, the Company received $846,400 of cash proceeds related to sale of 2,525,000 common stock units at $0.20 per unit and 1,897,772 common stock units at $0.18 per unit. Each $0.20 unit and $0.18 unit consists of a share of common stock and a warrant to purchase half a share of common stock at an exercise price of $0.30 and $0.27, respectively, for a period of three years from issuance. The common shares related to these unit sales have not yet been issued as of September 30, 2020. As a result of the down round provision in the convertible debt described above, the fair value of the warrants was estimated using a binomial model and were accounted for as a derivative liability, due to the potentially unlimited number of shares that can be issued upon conversion of the debt instruments. Total shares to be issued related to convertible debt converted and stock units was 11,089,433 as of September 30, 2020.

 

During the nine months ended September 30, 2020, the Company issued a total of 388,667 shares of common stock to an investment banker and the various lenders in connection with the convertible notes payable issued during the period. These shares had a fair value of $72,733 and were recorded as deferred finance costs. Additionally, 1,443,333 shares of common stock with a fair value of $288,667 were issued to the convertible note lenders under a share lending arrangement, which the company recorded as contra-equity. The shares may be returned to the Company if the debt is satisfied in full by the maturity date. If the debt is not repaid by the maturity date or an event of default occurs, the shares are concerned fully earned, and the fair value of the shares will be amortized in full to expense. In connection with the repayment of the December 2019 convertible note in June 2020, the lender returned 933,333 shares previously issued under the share lending arrangement, which were cancelled.

 

Stock Warrants

 

A summary of stock warrant information is as follows:

 

 

 

Aggregate

Number

 

 

Aggregate

Exercise

Price

 

 

Weighted

Average

Exercise

Price

 

Outstanding at December 31, 2019

 

 

5,785,714

 

 

$ 1,292,100

 

 

$ 0.22

 

Warrants issued due to reset provisions

 

 

3,480,953

 

 

$ 626,572

 

 

$ 0.18

 

Warrants issued with common stock units

 

 

2,211,389

 

 

$ 631,200

 

 

$ 0.29

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited and cancelled

 

 

-

 

 

 

-

 

 

 

-

 

Outstanding at September 30, 2020

 

 

11,478,056

 

 

$ 1,923,300

 

 

$ 0.17

 

 

 
15

Table of Contents

 

The weighted average remaining contractual life is approximately 2.86 years for stock warrants outstanding with a total intrinsic value of $2,897,483 on September 30, 2020. All of the above warrants were fully vested. During the nine months ended September 30, 2020, a total of 3,685,714 warrants associated with the June 2019 Notes had their exercise price reset to $0.18 as a result of the sale of common stock units described above.

 

Note 8: Related Party

 

Mark Adams, CEO, and David Hall, EVP of Sales invested in the June 2019 Notes. Mr. Adams and Mr. Hall contributed $250,000 and $100,000 respectively, and converted their debt during the nine months ended September 30, 2020 into shares of common stock of 1,388,885 and 555,555, respectively, that have not yet to be issued.

 

Note 9: Commitments

 

Employment Agreement

 

In December 2017, the Company entered into an employment agreement with Daniel Davis and Mark Adams. As of the Effective Date, and for one year of the date therefrom, the Executive’s annual salary shall be equal to $180,000 and $120,000, respectively, per annum (the “Annual Salary”). The Annual Salary shall be paid to the Executive in equal installments in accordance with the Company’s usual payroll practices.

 

Executive’s Annual Salary shall increase automatically at the rate of five percent (5%) per year for four years, beginning on the anniversary date of the Effective Date. In addition to the automatic raises set forth above, the Annual Salary may also be increased from time to time by merit and general increases in amounts determined by the Board.

 

Performance Bonus. In addition to the Annual Salary, the Executive is eligible to earn an annual bonus of up to thirty percent (30%) of Executive’s Annual Salary (the “Performance Bonus”). The amount of the Performance Bonus will be determined in good faith by the Board, based upon the following factors:

 

(a)

Fifty percent (50%) of the Performance Bonus shall be based upon the achievement of the Executive’s individual objectives, as defined in writing and presented to Executive annually by the Board.

 

 

(b)

Fifty percent (50%) of the Performance Bonus shall be based upon the achievement of Company objectives, which shall include specifically, meeting or exceeding the revenue targets and other objectives as determined by the Board.

 

The initial set of performance objectives, both for Executive individually and for the Company, will be reasonably established by the Board within sixty (60) days of the Effective Date of this Agreement. Subsequent performance objectives, both for Executive individually and for the Company, will be reasonably established by the Board within sixty (60) days of the beginning of the calendar year to which the Performance Bonus relates. The Performance Bonus shall be paid to Executive in the first regular payroll period after the Board makes a good faith determination that such Performance Bonus has been earned, but in no event shall the Performance Bonus be paid later than March 1 of the calendar year immediately following the calendar year in which the bonus was earned.

 

In addition to salary, the agreement provided for the option of 1,000,000 common shares of the Company, which shall vest at a rate of 28,000 share for each full one-month period worked from the Effective Date. If this Agreement is terminated pursuant to written notice by the Company to the Executive on or before the date that is one year after the Effective Date, all the options shall vest and the Executive shall retain the options subject to their terms and the terms hereof. The options may contain terms providing the issuer the right to accelerate vesting and/or require the exercise of options prior to the initial public offering and listing of the issuer. The Company may arrange for the grant of additional options to the Executive from time to time based on the Executive’s performance and other relevant factors as the Board may determine in its discretion.

 

 
16

Table of Contents

 

All options to purchase Holdings Shares granted to the Executive shall be subject to the terms of the stock option agreement pursuant to which they are granted and the terms of the stock option plan under which they are granted in effect from time to time. Shares issuable on exercise of the options shall be subject to any escrow, trading restriction, or other requirement imposed by any stock exchange or securities regulatory authority upon initial public offering or listing of the shares. The Executive shall take such steps and execute and deliver such documents as may be required to affect the foregoing.

 

The Company may terminate Executive’s employment for Cause immediately upon Notice from the Company to Executive. For purposes of this Agreement, “Cause” shall mean the occurrence of any of the following: (i) Executive’s conviction of or plea of nolo contendere to any felony crime involving fraud, dishonesty, or moral turpitude; (ii) Executive’s commission of, or participation in, a fraud against the Company. In the event Executive’s employment is terminated for Cause, the Company shall have no further obligations to the Executive other than to pay all compensation and expense reimbursements owing for services rendered and reasonable business expenses incurred by Executive prior to the effective date of such termination.

 

Upon termination of this agreement pursuant, the Company shall provide to the Executive:

 

 

(a)

A lump sum payment equal to the greater of (i) twelve (12) months’ Annual Salary at the Executive’s then- current rate, or (ii) Executive’s Annual Salary for the remainder of the Term;

 

 

 

 

(b)

if applicable, to the extent permitted by the Company’s group insurance carrier and applicable law, continued group insurance benefits coverage, together with reimbursement of the individual life insurance premium for the period of time equal to the number of months in respect of which payment is due pursuant and;

 

 

 

 

(c)

any other amounts (including but not limited to any earned Performance Bonus during the Executive’s active employment that may be payable pursuant to this Agreement) accrued and earned by the Executive prior to the effective date of termination.

 

If a Change of Control occurs and the Executive is not offered continued employment on a comparable basis after the Change of Control, the Executive shall be entitled to receive, within thirty (30) days after the Change of Control, a sum equivalent to twelve (12) months’ Annual Salary, plus an additional 4% of Annual Salary in lieu of benefits, and any Performance Bonus that has been earned by Executive prior to the effective date of the Executive’s termination from the Company. Thereafter, the Company shall have no further obligations to the Executive under this Agreement other than payment of any other amounts accrued as owing to the Executive under this Agreement as of the date the Change of Control occurs.

 

On May 31, 2019, the Company entered into a consulting agreement with Daniel Davis, a former executive of the Company, related to his departure from employment with the Company. The agreement requires Daniel Davis to provide limited consulting services to the Company for a period of up to three years beginning May 1, 2019 in exchange for $165,000 per year. During the nine months ended September 30, 2020, the Company and Daniel Davis agreed to accelerate the payment of a portion of the consulting agreement, with the maturity period ending three months earlier than the original agreement. The Company made payments of $151,250 during the nine months ended September 30, 2020, leaving a balance of $233,750, included in accounts payable and accrued expenses on the consolidated balance sheet. In addition, the Company entered into a lock up agreement with Daniel Davis that restricts the number of shares Daniel Davis can otherwise publicly sell for a period of up to three years to one third of the volume limits set forth under SEC Rule 144. Daniel Davis also agreed to a standstill agreement that provides that for a period of up to three years Daniel Davis will not seek to influence the governance of the Company, including by participation in any solicitation of other shareholders, promotion of any extraordinary transaction, nomination of any candidate to the Board or by seeking the removal of any existing directors.

 

Leases

 

The Company has a single operating lease for an office lease in Rancho Santa Margarita, California with an initial term of 37 months. Base monthly rent was approximately $3,200 per month plus net operating expenses. The office lease expired in February 2020, and the Company is currently continuing the lease on a month to month basis. Operating lease expense was $0 and $9,463 for the three months ended September 30, 2020 and 2019, respectively, and $9,463 and $28,389 for the nine months ended September 30, 2020 and 2019, respectively.

 

 
17

Table of Contents

 

The Company also maintains short-term rental agreements for certain storage facilities. Total rent expense for these rentals was $18,343 and $11,186 for the three months ended September 30, 2020 and 2019, respectively, and $40,256 and $33,099 for the nine months ended September 30, 2020 and 2019, respectively.

 

Note 10: Accrued Liabilities – Other

 

Prior to the Merger, China Grand Resorts, Inc. recorded various liabilities that were incurred by former related parties. The current management team is not aware of any written agreements in place governing the terms of the loans nor have they been in contact with the debt holders however recognizes that China Grand Resorts, Inc. previously reported these amounts as liabilities of the Company. In accordance with ASC 405-20-40, the liabilities may only be removed from the Company’s financial statements if they are paid, formally settled or judicially released. Management believes the relevant statute of limitations has passed and that no enforceable legal claim exists in relation to these liabilities of $1,642,118 but does not believes that is sufficient to remove the liability from the financial statements. Management does not intend to remove these liabilities of $1,642,118 from the Company’s financial statements until such time that the liability is formally settled or judicially released in accordance with ASC 405-20-40. Due to the lack of written agreements and other factors noted above, management concluded to no longer accrue interest on these loans.

 

Note 11: Subsequent Events

 

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.

 

 
18

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations include several forward-looking statements that reflect management’s current views with respect to future events and financial performance. You can identify these statements by forward-looking words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue,” or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

 

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the SEC. Important factors currently known to management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions. Factors that could cause differences include, but are not limited to, expected market demand for our products, fluctuations in pricing of our products, and competition.

 

The following discussion provides information that management believes is relevant to an assessment and understanding of our past financial condition and plan of operations. The discussion below should be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this report.

 

Overview

 

The Company was originally incorporated in the State of Nevada on September 21, 1989 under the name of Fulton Ventures, Inc. Since incorporated, the Company has engaged in a variety of businesses, but has been inactive since late 2014 through the Merger that closed on September 14, 2018. Since the Merger, the Company has been operated under the control of current management and continued to operate the business of Jacksam Corporation, described herein, as our sole business. Our sole business has been the design, manufacturing and sale of vaporizer cartridge filling machines, capping machines, other automation machines, and cartridges to customers in the medical and recreational cannabis, hemp, and CBD industries.

 

Basis of Presentation

 

The unaudited condensed consolidated financial statements of Jacksam Corporation as of September 30, 2020, and for the three and nine months ended September 30, 2020 and 2019, include a summary of our significant accounting policies and should be read in conjunction with the discussion below. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such unaudited interim periods have been included in these unaudited financial statements. All such adjustments are of a normal recurring nature. 

 

Components of Statements of Operations

 

Revenue

 

Machine revenue consists of sales of our eShark cartridge filling machine, 710 Shark cartridge filling machine, and 710 Captain cartridge capping machine. Consumable product revenue consists of royalty from strategic partners and sales of cartridges, accessories, warranty, service and freight charges. Revenue is net of returns, discounts and allowances. Once a sales order is negotiated and received by a sales representative, we generally collect a 50% deposit from the customer. When the product is ready to be shipped, the customer will generally pay the remaining balance. We recognize the revenue when the product leaves our and our strategic partners’ warehouse on the way to the customer.

 

For the filling and capping machines, training is coordinated with the customers in accordance with their availability but generally completed within a week or two of the shipment. Standard warranties are offered at no cost to customers to cover parts for three years, and labor and maintenance are offered for one year for product defects.

 

 
19

Table of Contents

 

Cost of Revenue

 

Cost of goods sold represents costs directly related to supplies and materials, machines, freight and delivery, commissions, printing, packaging and other costs.

 

We expect our cost of goods sold per unit to decrease as we continue to scale our operations, improve product designs and work with our third-party suppliers to lower costs.

 

Operating Expenses

 

Sales and Marketing. Sales and marketing expenses consist primarily of compensation, benefits, travel and other costs for our direct sales force and project managers. Sales and marketing expenses also include costs associated with our business development efforts with our distributors and partners and costs related to trade shows and other marketing programs. We expense sales and marketing costs as incurred. We expect sales and marketing expenses to increase in future periods as we expand our sales and marketing teams and increase our participation in global trade shows and other marketing programs.

 

General and Administrative. Our general and administrative expenses consist primarily of compensation, benefits, travel and other costs for employees with non-sales roles. In addition, general and administrative expenses include third-party consulting, legal, audit, accounting services, and allocations of overhead costs, such as rent, facilities and information technology. In the near term, we expect general and administrative expenses to decrease driven by our cost reduction initiatives. In the long term, we expect general and administrative expenses to increase as we grow our business.

 

Interest Expense

 

Interest expense consists primarily of interest from notes due to debtholders.

 

Results of Operations – Three Month Periods

 

Comparison for the three-month periods ended September 30, 2020 and 2019: 

 

Revenue

 

Total revenue during the three months ended September 30, 2020 decreased to $735,604 (comprised of machine sales of $685,635 and consumable product sales of $49,969), compared to the three months ended September 30, 2019 that generated sales of $1,303,053 (comprised of machine sales of $945,199 and consumable product sales of $357,854).

 

The decrease in sales was mainly due to the Company strategically phased out selling proprietary cartridge products and now focused on providing automation solutions with our filling and capping machines and pre-racked cartridges.

 

The total revenue of $735,604 does not include a royalty of $97,980 we received from a strategic partner in late September for the cannabis pre-roll filling machine we sold during the third quarter of 2020. The $97,980 was recognized under Deferred Revenue as of September 30, 2020.

 

 
20

Table of Contents

 

Cost of Revenue

 

Total cost of revenue decreased to $331,863 during the three months ended September 30, 2020, compared to the three months ended September 30, 2019 that had costs of revenues of $818,442. The decrease in cost of revenue was mainly due to the Company strategically phased out selling proprietary cartridge products.

 

Under the Company’s current and new business model, the Company focuses on selling high-margin automation machines. As a result, our gross margin percentage increased from 37% for the three months ended September 30, 2019 to 55% for the three months ended September 30, 2020.

 

Operating Expenses

 

Sales, Marketing and General and Administrative. Sales, Marketing and General and Administrative expenses during the three months ended September 30, 2020 decreased to $500,623 (comprised of Salaries of $306,307 and other SG&A expenses of $194,316), compared to the three months ended September 30, 2019 that produced $933,547 in expenses (comprised of $465,339 in salaries and other SG&A expenses of $468,208).

 

The decrease in salaries was related to a less amount of commission paid to sales representatives as the Company phased out proprietary cartridge products. And the decrease in other SG&A expenses was comprised primarily of the following: decreased travel and trade show spending due to the COVID-19 and other operating cost disciplines.

 

Income (loss) from Operations

 

Total loss from operations was $96,882 during the three months ended September 30, 2020, compared to $448,936 for the three months ended September 30, 2019.

 

The decreased loss from operations was primarily the result of the gross margin improvement and operating cost disciplines.

 

Derivative Gain (loss)

 

Derivative loss, a non-cash expense, was $2,000,866 during the three months ended September 30, 2020, due to the fair value change of the debt and warrants of the June 2019 Notes driven by the stock price increase between June 30, 2020 and September 30, 2020, compared to a $5,047,111 derivative loss for the three months ended September 30, 2019.

 

Interest Expense

 

Interest expense, a non-cash expense, decreased to $67,945 during the three months ended September 30, 2020, compared to $448,430 for the three months ended September 30, 2019, primarily due to a decreased amount of amortization of debt discount of the 2019 Notes.

 

 
21

Table of Contents

 

Results of Operations – Nine Month Periods

 

Comparison for the nine-month periods ended September 30, 2020 and 2019: 

 

Revenue

 

Total revenue during the nine months ended September 30, 2020 decreased to $2,022,307 (comprised of machine sales of $1,802,305 and consumable product sales of $200,002), compared to the nine months ended September 30, 2019 that generated sales of $4,253,728 (comprised of machine sales of $2,166,652 and consumable product sales of $2,087,076).

 

As described above, the decrease in sales was mainly due to the Company phased out selling proprietary cartridge products and now focused on providing automation solutions.

 

In addition, the outbreak of COVID-19 in China since January 2020 caused a pause of shipment from China to the U.S for certain of our products manufactured in China. And the later outbreak of COVID-19 in the U.S. caused different levels of delay in the operation of the Company, vendors, and customers. These factors adversely impacted the financial performance of the Company for the nine months ended September 30, 2020.

 

Cost of Revenue

 

Total cost of revenue decreased to $879,637 during the nine months ended September 30, 2020, compared to the nine months ended September 30, 2019 that had costs of revenues of $3,341,083.

 

As described above, the decrease in cost of revenue was mainly due to the Company strategically phased out selling proprietary cartridge products.

 

Under the Company’s current and new business model, our gross margin percentage increased from 21% for the nine months ended September 30, 2019 to 57% for the nine months ended September 30, 2020.

 

Operating Expenses

 

Sales, Marketing and General and Administrative. Sales, Marketing and General and Administrative expenses during the nine months ended September 30, 2020 decreased to $1,347,158 (comprised of Salaries of $786,004 and other SG&A expenses of $561,154), compared to the nine months ended September 30, 2019 that produced $3,919,991 in expenses (comprised of $2,169,334 in salaries and other SG&A expenses of $1,750,657).

 

During the three months ended June 30, 2019, the Company recognized one-time charges of the following: settlement fees with the founder and another former employee of approximately $600,000, legal fees associated with the settlement of approximately $100,000, and R&D fees for the eShark cartridge filling machine and new cartridge products of approximately $100,000. Excluding these one-time charges, the decrease in salaries for the nine months ended September 30, 2020 was related to a less amount of commission paid to sales representatives as the Company phased out proprietary cartridge products. And the decrease in other SG&A expenses was comprised primarily of the following: decreased travel and trade show spending due to the COVID-19 and other operating cost disciplines.

 

Income (loss) from Operations

 

Total loss from operations was $204,488 during the nine months ended September 30, 2020, compared to $3,007,346 for the nine months ended September 30, 2019.

 

The decreased loss from operations was primarily the result of the gross margin improvement and operating cost disciplines.

 

 
22

Table of Contents

 

Derivative Loss

 

Derivative loss, a non-cash expense, was $3,512,675 during the nine months ended September 30, 2020, driven by the stock price increase between December 31, 2019 and September 30, 2020, compared to $5,181,924 for the nine months ended September 30, 2019.

 

Interest Expense

 

Interest expense, a non-cash expense, increased to $1,684,857 during the nine months ended September 30, 2020, compared to $516,207 for the nine months ended September 30, 2019, primarily due to an increased amount of amortization of debt discount of the 2019 Notes.

 

Liquidity and Capital Resources

 

At September 30, 2020, we had cash and cash equivalents of $598,964. To date, we have financed our operations principally through receipts of customer payments and borrowing on credit facilities, debt of $650,900, issuance of equity of $1,303,900, and issuances of convertible debt of $6,498,066.

 

We anticipate that we will need additional financing to continue as an ongoing entity over the next 12 months. Our future capital requirements and the adequacy of available funds will depend on many factors. There can be no assurance we will be able to obtain additional financing on favorable terms, or at all. If we are unable to obtain additional financing, our financial results and business prospects may be materially adversely affected.

 

Operating Activities

 

We have historically experienced negative cash outflows. Our net cash used in operating activities primarily results from our operating losses combined with changes in working capital components as we have grown our business and is influenced by the timing of cash payments for inventory purchases and cash receipts from our customers. Our primary source of cash flow from operating activities is cash down payments and final payments for our machines. Our primary uses of cash from operating activities are employee-related expenditures and amounts due to vendors for purchased components. Our cash flows from operating activities will continue to be affected principally by our working capital requirements and the extent to which we build up our inventory balances and increase spending on personnel and other operating activities as our business grows.

 

During the nine months ended September 30, 2020, operating activities used $919,133 in cash, a decrease of $882,956 from cash used in the nine months ended September 30, 2019 of $1,802,089.

 

Investing Activities

 

The Company had no investing activities in either period.

 

Financing Activities

 

During the nine months ended September 30, 2020, the Company received $388,900 in proceeds from convertible debt, $591,900 in proceeds from non-convertible debt, and $846,400 in proceeds from sale of common stock units, and made payments of $630,000 of convertible notes payable, $89,426 of non-convertible notes payable, and $43,300 of debt issuance costs.

 

During the nine months ended September 30, 2019, the Company received $1,791,666 in proceeds from convertible debt and a $2,900 payment related to the exercise of 2,900,000 warrants, and made payments of $70,912 of non-convertible notes payable, $130,000 convertible notes payable, and $132,848 of debt issuance costs.

 

 
23

Table of Contents

 

Off-Balance Sheet Arrangements

 

During the nine months ended September 30, 2020 and the year ended December 31, 2019, we did not have any off-balance sheet arrangements as defined by applicable SEC regulations.

 

Item 3. Quantitative and Qualitative Disclosure About Market Risk

 

We do not use derivative financial instruments in our investment portfolio and have no foreign exchange contracts. Our financial instruments consist of cash and cash equivalents. We consider investments that, when purchased, have a remaining maturity of ninety (90) days or less to be cash equivalents. We do not believe that a notional or hypothetical 10% change in interest rates would have a material impact on our interest income.

 

Item 4. Controls and Procedures

 

Management’s Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Form 10-Q, we have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

 
24

Table of Contents

 

PART II — OTHER INFORMATION

 

Item 1. Legal Proceedings

 

There are presently no material pending legal proceedings to which the Company is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

 

Item 1A. Risk Factors

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3. Defaults Upon Senior Securities

 

Not applicable.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

 
25

Table of Contents

 

Item 6. Exhibits

 

Exhibit Number

 

Exhibit Description

 

31.1

Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020

 

31.2

Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020

 

32.1

Certification of the Company’s Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002

 

101

 

Interactive data files pursuant to Rule 405 of Regulation S-T

 

 
26

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

JACKSAM CORPORATION

 

 

Dated: November 10, 2020

By:

/s/ Mark Adams

 

Mark Adams

 

Chief Executive Officer

 

 

Dated: November 10, 2020

By:

/s/ Michael Sakala

 

Michael Sakala

 

Chief Financial Officer

 

 
27